PD-L1 Protein (AA 19-238) (His tag)
-
- Target See all PD-L1 Proteins
- PD-L1 (CD274 (PD-L1))
- Protein Type
- Recombinant
- Biological Activity
- Active
- Protein Characteristics
- AA 19-238
-
Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- This PD-L1 protein is labelled with His tag.
- Sequence
- AA 19-238
- Characteristics
- This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 26 kDa. The protein migrates as 35-42 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- Purity
- >98 % as determined by SDS-PAGE.
- Sterility
- 0.22 μm filtered
- Endotoxin Level
- Less than 1.0 EU per μg by the LAL method.
- Grade
- HPLC verified
- Top Product
- Discover our top product PD-L1 Protein
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4
- Handling Advice
- Please avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
-
-
PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging." in: The Analyst, Vol. 146, Issue 9, pp. 2910-2918, (2021) (PubMed).
: "Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. ..." in: Nature medicine, Vol. 26, Issue 5, pp. 732-740, (2020) (PubMed).
: "Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." in: Cancer immunology, immunotherapy : CII, (2020) (PubMed).
: "Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair." in: Neurochemical research, Vol. 44, Issue 11, pp. 2470-2481, (2019) (PubMed).
: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." in: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).
: "A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects." in: Molecular therapy. Nucleic acids, Vol. 5, Issue 12, pp. e397, (2016) (PubMed).
: "
-
PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging." in: The Analyst, Vol. 146, Issue 9, pp. 2910-2918, (2021) (PubMed).
-
- Target
- PD-L1 (CD274 (PD-L1))
- Alternative Name
- PD-L1 (PD-L1 Products)
- Synonyms
- B7-H Protein, B7H1 Protein, PD-L1 Protein, PDCD1L1 Protein, PDCD1LG1 Protein, PDL1 Protein, A530045L16Rik Protein, B7h1 Protein, Pdcd1l1 Protein, Pdcd1lg1 Protein, Pdl1 Protein, RGD1566211 Protein, CD274 molecule Protein, CD274 antigen Protein, programmed cell death 1 ligand 2 Protein, CD274 Protein, Cd274 Protein, PDCD1LG2 Protein
- Background
- Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.
- Molecular Weight
- 26.0 kDa
- NCBI Accession
- NP_054862
- Pathways
- Cancer Immune Checkpoints
-